… of SARS-CoV-2 was recognized immediately upon discovery, … literally as soon as
recombinant SARS-CoV-2 spike protein … These antibodies to SARS-CoV-2 all target the receptor-…

… on the discovery, spread, … immunotherapies and other treatments and vaccine development.
An epidemiological survey revealed a potentially large number of asymptomatic SARS-CoV-…

… immunotherapies that use antibodies, with the hope of pointing out the future direction of
immunotherapy… Vojdani and Kharrazian [99] discovered that 21 out of 50 human tissue antigens …

… for SARS-CoV and RaTG13, respectively. SARS-CoV-2 has been shown to use the SARS-CoV …
In this review, innate immunity in SARS-Cov-2 infection was discussed through Siglecs, …

… The novel coronavirus SARS-CoV-2 emerged in China in … It is unclear whether antibodies
induced by SARS-CoV-2 have … seasonal HCoV may cross-neutralize SARS-CoV-2. Data from …

… SARS-CoV-2 is an enveloped positivesense single-stranded … pharmacotherapeutic approaches
to fight SARSCoV-2 [10, 12… the changes can be a way to discover future useful drugs, the …

… To support HuNAb-based immunotherapy, passive immunization using convalescent …
in the discovery of HuNAb have resulted in HuNAb-based clinical immunotherapy for COVID-19 …

… We also investigated the association between ACE2 expression and immunotherapy …
ACE2 and cancer and the potential association between cancer and SARS-CoV-2 infection. …

… of Innovative Immunotherapy (Immune Checkpoint Inhibitors, ICIs) in promoting severe
SARS-CoV-2 infection is in fact source of debate. As we know, Innovative Immunotherapy, based …

… Also, challenges of the immune response to SARS‐CoV‐2 leading to dysfunctional immune
… against SARS‐CoV‐2 and its dysfunction, we introduce potential immunotherapies as well …